Search Results

Lisata Therapeutics, Inc. announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

On January 29th, the results of the phase II study on Qilu Pharmaceutical’s novel anticancer drug iparomlimab and tuvonralimab were published online in Signal Transduction and Targeted Therapy.

Recently, the results of the Phase I study for iparomlimab, developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journal Frontiers in Immunology.

The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase -positive non-small cell lung cancer, have recently been featured in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Data from Qilu Pharmaceutical’s clinical trial of its novel bifunctional antibody, QL1706 (iparomlimab and tuvonralimab), will be unveiled during a mini oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress 2023.